Adam8 mAb also lowered AFP; slowed the progression of HCC; induced the expression of Casp3, Bax, and P53; and inhibited the expression of VEGF-A, PCNA, and Bcl2 in mouse livers. Here, ADAM8 is linked to hepatocellular carcinoma.